厄洛替尼治疗的非小细胞肺癌（NSCLC）患者中C-erbB-3的表达

C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.

作者信息

CsToth Ingrid, Anthoine Géraldine, Berghmans Thierry, Mascaux Céline, Paesmans Marianne, Sculier Jean-Paul, Meert Anne-Pascale

机构信息

Département d'Oncologie Thoracique et Soins Intensifs et Data Centre,Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

出版信息

Anticancer Res. 2011 Jan;31(1):281-5.

PMID:21273611

Abstract

BACKGROUND

The clinical impact of c-erbB-3 has seldom been assessed in patients with non small cell lung cancer (NSCLC).

PATIENTS AND METHODS

Forty-three NSCLC patients treated by erlotinib for c-erbB-3 and EGFR expression were investigated by immunohistochemistry analysis.

RESULTS

Two partial responses, one minor response, two stable diseases and twenty progressive diseases were observed at the first evaluation. Seventeen patients died before evaluation. Median EGFR expression was 70% of the cancer cells. Forty-two percent of the tumours co-expressed c-erbB-3 and EGFR without any difference according to histology or disease stage. There was no correlation between c-erbB-3 and EGFR expression. Median survival time was 2.6 months and the six months survival rate was 21%. There was no detectable impact of EGFR (p=0.94) or c-erbB-3 (p=0.93) expression on survival.

CONCLUSION

In this small particular cohort of NSCLC patients receiving salvage therapy with erlotinib, there was no correlation between c-erbB-3 expression and clinical parameters, nor between cerbB-3/EGFR expression and outcome.

摘要

背景

c-erbB-3在非小细胞肺癌（NSCLC）患者中的临床影响鲜有评估。

患者与方法

对43例接受厄洛替尼治疗的NSCLC患者进行免疫组织化学分析，以研究c-erbB-3和表皮生长因子受体（EGFR）的表达情况。

结果

首次评估时观察到2例部分缓解、1例轻微缓解、2例病情稳定及20例病情进展。17例患者在评估前死亡。EGFR表达的中位数为癌细胞的70%。42%的肿瘤同时表达c-erbB-3和EGFR，在组织学或疾病分期方面无差异。c-erbB-3与EGFR表达之间无相关性。中位生存时间为2.6个月，6个月生存率为21%。EGFR（p=0.94）或c-erbB-3（p=0.93）表达对生存无明显影响。